MedPath

A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children

Phase 2
Completed
Conditions
HIV Infections
Registration Number
NCT00000913
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

The purpose of this study is to determine the safety and effectiveness of a soft-gel capsule formulation of saquinavir (SQV-SGC), a protease inhibitor, when given in combination with other anti-HIV drugs.

SQV-SGC has been tested in adults for the treatment of HIV infection, but more information is still needed about SQV-SGC in children. Recent studies suggest that this soft-gel capsule form may be safer and more effective than other protease inhibitors.

Detailed Description

Clinical trials in adults and children suggest that SQV-SGC has advantages over other protease inhibitors in terms of tolerability, safety, and effectiveness in patients who have failed therapy with other protease inhibitors. \[AS PER AMENDMENT 11/24/99: Pharmacokinetic data from this study demonstrate lower than expected plasma SQV exposures, particularly in Arm 1. Based on these data, patients in the study will be offered the opportunity to adjust their doses. Ritonavir added to the Arm 1 regimen is expected to significantly increase SQV-SGC plasma levels and allow twice-daily dosing for SQV-SGC.\]

Patients are randomized to one of two study arms. Patients in Arm 1 receive SQV-SGC plus two \[AS PER AMENDMENT 11/24/99: one or two\] NRTIs of choice. Patients in Arm 2 receive SQV-SGC plus NFV plus one or two NRTIs of choice. All participants are evaluated by physical examinations and laboratory tests during the study and are followed for incidence of death, cancer, or fetal abnormality. NRTIs are not provided as part of this study. \[AS PER AMENDMENT 11/24/99: This study is closed to accrual. All subjects on follow-up (Cohort 1) are given the option of either discontinuing participation in ACTG 397 or participating in the next phase of the study (version 2.0). Those electing to continue participation constitute Cohort 1A. The adjusted Arm 1 regimen consists of SQV-SGC plus ritonavir plus one or two NRTIs. Ritonavir is not provided as part of this study. The Arm 2 regimen study drugs have not changed but the maximum allowable dose of SQV-SGC has increased from 1,200 mg twice-daily to 1,600 mg twice-daily. Participants continue to be followed with physical examinations and laboratory evaluations that include an intensive pharmacokinetics study on Day 14 of the new regimen.\]

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (36)

Emory Univ Hosp / Pediatrics

๐Ÿ‡บ๐Ÿ‡ธ

Atlanta, Georgia, United States

Cook County Hosp

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Chicago Children's Memorial Hosp

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

UCSF / Moffitt Hosp - Pediatric

๐Ÿ‡บ๐Ÿ‡ธ

San Francisco, California, United States

Univ of Alabama at Birmingham / Childrens Hosp of AL

๐Ÿ‡บ๐Ÿ‡ธ

Birmingham, Alabama, United States

Los Angeles County - USC Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Children's Hosp of Oakland

๐Ÿ‡บ๐Ÿ‡ธ

Oakland, California, United States

Columbia Presbyterian Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Children's Hospital & Medical Center / Seattle ACTU

๐Ÿ‡บ๐Ÿ‡ธ

Seattle, Washington, United States

Med College of Virginia

๐Ÿ‡บ๐Ÿ‡ธ

Richmond, Virginia, United States

Univ of Illinois College of Medicine / Pediatrics

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Univ of Alabama at Birmingham - Pediatric

๐Ÿ‡บ๐Ÿ‡ธ

Birmingham, Alabama, United States

Long Beach Memorial (Pediatric)

๐Ÿ‡บ๐Ÿ‡ธ

Long Beach, California, United States

Yale Univ Med School

๐Ÿ‡บ๐Ÿ‡ธ

New Haven, Connecticut, United States

Univ of Miami (Pediatric)

๐Ÿ‡บ๐Ÿ‡ธ

Miami, Florida, United States

Howard Univ Hosp

๐Ÿ‡บ๐Ÿ‡ธ

Washington, District of Columbia, United States

Univ of Maryland at Baltimore / Univ Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Baltimore, Maryland, United States

Tulane Univ / Charity Hosp of New Orleans

๐Ÿ‡บ๐Ÿ‡ธ

New Orleans, Louisiana, United States

Children's Hosp of Boston

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Baystate Med Ctr of Springfield

๐Ÿ‡บ๐Ÿ‡ธ

Springfield, Massachusetts, United States

Univ of Mississippi Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Jackson, Mississippi, United States

Univ of Medicine & Dentistry of New Jersey / Univ Hosp

๐Ÿ‡บ๐Ÿ‡ธ

Newark, New Jersey, United States

Bronx Municipal Hosp Ctr/Jacobi Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Bronx, New York, United States

Children's Hosp at Albany Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Albany, New York, United States

North Shore Univ Hosp

๐Ÿ‡บ๐Ÿ‡ธ

Great Neck, New York, United States

Bronx Lebanon Hosp Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Bronx, New York, United States

Incarnation Children's Ctr / Columbia Presbyterian Med Ctr

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Harlem Hosp Ctr

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

State Univ of New York at Stony Brook

๐Ÿ‡บ๐Ÿ‡ธ

Stony Brook, New York, United States

Cornell Univ Med College

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Saint Christopher's Hosp for Children

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

Med Univ of South Carolina

๐Ÿ‡บ๐Ÿ‡ธ

Charleston, South Carolina, United States

Ramon Ruiz Arnau Univ Hosp / Pediatrics

๐Ÿ‡ต๐Ÿ‡ท

Bayamon, Puerto Rico

Univ of Puerto Rico / Univ Children's Hosp AIDS

๐Ÿ‡ต๐Ÿ‡ท

San Juan, Puerto Rico

Palm Beach County Health Dept

๐Ÿ‡บ๐Ÿ‡ธ

Riviera Beach, Florida, United States

San Juan City Hosp

๐Ÿ‡ต๐Ÿ‡ท

San Juan, Puerto Rico

ยฉ Copyright 2025. All Rights Reserved by MedPath